Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oxidants and COPD.

William MacNee1

  • 1ELEGI, Colt Research Laboratories, MRC Centre for Inflammation Research, University of Edinburgh, Medical School, Edinburgh, Scotland, UK. w.macnee@ed.ac.uk

Current Drug Targets. Inflammation and Allergy
|February 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GOLD 2026 COPD ABE assessment tool to identify individuals at high risk in a UK multicentre COPD cohort (ERICA).

BMJ open respiratory research·2026
Same author

Dysregulation of lipid mediators in patients with frequent exacerbations of COPD.

ERJ open research·2025
Same author

Contrasting the clinical and biological characteristics of young and old COPD patients.

ERJ open research·2025
Same author

The recognition of lung disease in coal workers: The role of Gough-Wentworth whole lung sections.

The journal of the Royal College of Physicians of Edinburgh·2022
Same author

Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).

Trials·2022
Same author

Cardiovascular risk prediction using physical performance measures in COPD: results from a multicentre observational study.

BMJ open·2020
Same journal

Emerging targets for COPD therapy.

Current drug targets. Inflammation and allergy·2007
Same journal

Animal models of pulmonary emphysema.

Current drug targets. Inflammation and allergy·2007
Same journal

Epithelial mucus-hypersecretion and respiratory disease.

Current drug targets. Inflammation and allergy·2007
Same journal

Lung structural changes in chronic obstructive pulmonary diseases.

Current drug targets. Inflammation and allergy·2007
Same journal

Inflammatory mediators in chronic obstructive pulmonary disease.

Current drug targets. Inflammation and allergy·2007
Same journal

Inflammatory cells and chronic obstructive pulmonary disease.

Current drug targets. Inflammation and allergy·2007
See all related articles

Smoking causes chronic obstructive pulmonary disease (COPD) through increased oxidative stress in the lungs and body. Antioxidant therapy is needed to target this oxidative stress for effective COPD treatment.

Area of Science:

  • Pulmonary Medicine
  • Oxidative Stress Research
  • Pharmacology

Background:

  • Smoking is the primary cause of chronic obstructive pulmonary disease (COPD).
  • Cigarette smoke generates significant oxidative stress in the lungs, worsening inflammation and lung cell damage.
  • Oxidative stress in COPD patients contributes to lung injury, mucus overproduction, antiprotease inactivation, and systemic effects like muscle dysfunction.

Purpose of the Study:

  • To highlight the critical role of oxidative stress in COPD pathogenesis.
  • To emphasize the systemic impact of oxidative stress in COPD.
  • To underscore the need for effective antioxidant therapies in managing COPD.

Main Methods:

  • Review of existing evidence on oxidative stress in COPD.

Related Experiment Videos

  • Analysis of the mechanisms linking oxidative stress to COPD symptoms and systemic manifestations.
  • Identification of therapeutic targets for antioxidant interventions.

    • Main Results:

    • Increased oxidative burden is evident in the lungs of COPD patients.
    • Oxidative stress contributes to direct lung cell injury, mucus hypersecretion, and inflammation.
    • Systemic oxidative stress contributes to COPD-related skeletal muscle dysfunction and weight loss.

    Conclusions:

    • Oxidative stress is a key factor in both pulmonary and systemic aspects of COPD.
    • Modulating oxidative stress via antioxidant therapy presents a promising therapeutic avenue for COPD.
    • Targeting oxidative stress could alleviate lung damage and systemic complications in COPD patients.